Modality
mRNA
MOA
WRNi
Target
GLP-1R
Pathway
RNA Splicing
ALSGBMHeart Failure
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
~Sep 2018
→ ~Dec 2019
Phase 3
~Mar 2020
→ ~Jun 2021
NDA/BLA
~Sep 2021
→ ~Dec 2022
Approved
Mar 2023
→ Dec 2027
ApprovedCurrent
NCT04067972
2,455 pts·GBM
2023-03→2027-12·Terminated
2,455 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2027-12-121.7y awayPh3 Readout· GBM
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Approved
Termina…
Catalysts
Ph3 Readout
2027-12-12 · 1.7y away
GBM
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04067972 | Approved | GBM | Terminated | 2455 | CfB |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| BMY-7975 | Bristol-Myers Squibb | Phase 1 | MALT1 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Mavuglumide | Bayer | Approved | GLP-1R |